Zoetis investors face July 27 deadline in securities fraud suit

Zoetis Inc. faces a securities fraud class action lawsuit alleging the animal health company misled investors about weakening prescription growth and market share losses across its key product lines, according to court filings.

"The company's public statements were false and materially misleading throughout the class period," the complaint states. Investors who purchased Zoetis securities between Jan. 14, 2025, and May 6, 2026, are eligible to seek lead plaintiff status by July 27.

The lawsuit, filed by multiple shareholder rights firms including The Schall Law Firm and Kessler Topaz Meltzer & Check, alleges Zoetis made material misstatements concerning product adoption. The company's Librela medication for canine osteoarthritis suffered from weakening veterinarian prescription growth after the U.S. Food and Drug Administration issued safety warnings about neurological complications in dogs. Zoetis' Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology treatments lost ground to newly launched competing products for dogs.

Zoetis, a $75 billion animal health company spun off from Pfizer in 2013, derives a significant portion of its revenue from its dermatology and osteoarthritis portfolios. The class action claims the company failed to disclose the severity of competitive pressures and regulatory headwinds facing its core product lineup. The lawsuit seeks unspecified damages for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

The allegations signal heightened scrutiny of Zoetis' product pipeline and competitive positioning in the animal health sector. Investors will watch for the company's next quarterly filing and any disclosure of legal reserves tied to the litigation.

This article is for informational purposes only and does not constitute investment advice.